Tenon Medical (TNON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Jul, 2026Voting matters and shareholder proposals
Majority of voting power present or represented by proxy is required to approve the Auditor Appointment, Debt Financing, Future Financings, and Reverse Stock Split Proposals; abstentions count as votes against these proposals.
Majority of votes cast is required for the Adjournment Proposal; abstentions have no effect on this proposal.
Brokerage firms have discretionary authority to vote unvoted shares on the Auditor Appointment and Reverse Stock Split Proposals, but not on other proposals.
Broker non-votes have no effect on non-routine proposals.
Audit committee and external auditor matters
Stockholder ratification is not required for the appointment of the independent registered public accounting firm, but if not ratified, the audit committee will reconsider the appointment.
Haskell and White LLP is proposed as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Latest events from Tenon Medical
- Registering up to $100M in securities, targeting SI joint market, but faces financial and listing risks.TNON
Registration filing - All director nominees and proposals were approved, with no questions raised by stockholders.TNON
AGM 2026 - Raising up to $3.5M via shares and warrants to fund growth, repay debt, and address Nasdaq compliance.TNON
Registration filing - Board seeks approval for director elections, reverse stock split, and key financing proposals.TNON
Proxy filing - IPO offers shares and warrants to fund expansion, repay debt, and support R&D amid Nasdaq risks.TNON
Registration filing - Registering 6.3M shares for resale, company targets SI joint market but faces dilution and going concern risks.TNON
Registration filing - Shareholders will vote on director elections, a reverse stock split, and key financing approvals.TNON
Proxy filing - Q1 2026 revenue up 90% to $1.4M, gross margin 68.5%, net loss narrowed, liquidity risks remain.TNON
Q1 2026 - Q2 revenue up 21%, gross margin at 52%, but going concern risk remains.TNON
Q2 2024